Published Technical Disclosure Archive

pDNA Vaccines for Cancer, Autoimmune Diseases, and Infectious Diseases

Publication ID: 24-11857621_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “pDNA Vaccines for Cancer, Autoimmune Diseases, and Infectious Diseases,” Published Technical Disclosure No. 24-11857621_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857621_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,621.

Summary of the Inventive Concept

The present inventive concept leverages the core technology of synthetic pDNA vaccines against COVID-19 to develop novel treatments and diagnostic tools for cancer, autoimmune diseases, and infectious diseases.

Background and Problem Solved

The original patent disclosed synthetic pDNA vaccines against COVID-19, demonstrating their potential in inducing immune responses. However, the patent's scope was limited to SARS-CoV-2. The present inventive concept addresses the need for novel applications of pDNA vaccines in distinct fields, including cancer, autoimmune diseases, and infectious diseases, where conventional treatments often have limited efficacy or significant side effects.

Detailed Description of the Inventive Concept

The inventive concept involves engineering pDNA vaccines to express fusion proteins comprising tumor-associated antigens, self-antigens, or pathogen-specific antigens, and a SARS-CoV-2 S protein epitope. These pDNA vaccines can induce immune responses against the respective antigens, providing a therapeutic or prophylactic approach for cancer, autoimmune diseases, and infectious diseases. The system, method, composition, device, and kit claims outline specific implementations of this concept, highlighting its versatility and broad applicability.

Novelty and Inventive Step

The new claims introduce a novel combination of pDNA vaccine technology with distinct disease areas, creating an inventive step beyond the original patent's scope. The fusion of a SARS-CoV-2 S protein epitope with various antigens enables the pDNA vaccines to harness the immune system's response to SARS-CoV-2 and redirect it against the targeted disease.

Alternative Embodiments and Variations

Alternative embodiments may include using different SARS-CoV-2 epitopes, varying the antigen composition, or incorporating additional immune-stimulatory elements. Variations may also involve adapting the pDNA vaccine platform for specific disease indications or combining it with other therapeutic approaches.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in cancer, autoimmune diseases, and infectious diseases. The market for these applications is substantial, with an estimated global value exceeding tens of billions of dollars.

CPC Classifications

SectionClassGroup
A A61 A61K39/215
A A61 A61K9/0019
A A61 A61P31/14
C C07 C07K14/005
A A61 A61K2039/53
A A61 A61K2039/54
A A61 A61K2039/545
C C12 C12N2770/20022
C C12 C12N2770/20034
C C12 C12N2770/20071

Field of Art

Molecular biology, immunology, and vaccine development, with expertise in plasmid DNA (pDNA) vaccine design, antigen engineering, and immunological targeting strategies

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or immunology, experienced in genetic engineering, protein design, vaccine development, and understanding of immune system interactions

Obviousness Rationale

A PHOSITA would recognize the inherent adaptability of pDNA vaccine platforms for targeting diverse disease contexts by leveraging the established SARS-CoV-2 S protein epitope technology. The core innovation of the source patent provides a foundational template for engineering immunogenic fusion proteins across different disease domains. Given the known modularity of pDNA vaccine design and the well-understood principles of antigen presentation, extending the technology to cancer, autoimmune diseases, and other infectious diseases represents a predictable variation within the technological paradigm.

Obvious Combinations & Variations

Source Patent Element
Synthetic pDNA vaccine using SARS-CoV-2 spike protein sequences
PTD Variation
Fusion of SARS-CoV-2 S protein epitope with tumor-associated antigens for cancer immunotherapy
Obviousness Reasoning
Known protein engineering techniques enable modular antigen design, and immunological principles suggest that incorporating a highly immunogenic epitope could enhance vaccine efficacy across different disease contexts
Source Patent Element
Plasmid DNA encoding specific genetic sequences for immune targeting
PTD Variation
Adapting pDNA platform to induce immune tolerance for autoimmune disease and allograft rejection prevention
Obviousness Reasoning
Predictable application of existing vaccine technology to modulate immune responses through strategic antigen presentation, representing a logical extension of the original vaccine design principles
Source Patent Element
Genetic engineering of immunogenic sequences for vaccine development
PTD Variation
Expanding pDNA vaccine approach to emerging infectious disease antigen targeting
Obviousness Reasoning
Demonstrates a systematic, predictable approach to vaccine platform technology that a skilled practitioner would recognize as an obvious technological progression
Source Patent Element
Sequence optimization for improved immunogenicity
PTD Variation
Incorporating immune-stimulatory elements and exploring alternative SARS-CoV-2 epitopes
Obviousness Reasoning
Represents standard design optimization strategies well-known in vaccine development, involving iterative refinement of immunogenic components
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857621 and the disclosed pDNA vaccine platform, a person of ordinary skill in the art would find the variations presented herein obvious and anticipated, as they represent predictable extensions of established molecular vaccine design principles using known genetic engineering techniques. The systematic adaptation of the core pDNA vaccine technology to diverse disease contexts demonstrates no inventive step beyond the ordinary capabilities of skilled practitioners in the field.

Original Patent Information

Patent NumberUS 11,857,621
TitleSynthetic pDNA vaccines against COVID-19
Assignee(s)Imam Abdulrahman Bin Faisal University